Presented in: SPIE BIOS 2023
Authors: Elias Kokko, Robert Perttilä, Zoe Ylöniemi, Visa Kaivosoja, Jukka-Pekka Alanko, Petteri Uusimaa, Modulight Corp.
Non-muscle invasive bladder cancer (NMIBC) is a form of cancer with a relatively high 5-year survival rate but also very high recurrence rate. Photodynamic diagnosis is commonly used in standard clinical practice to visualize bladder cancer lesions as part of a TURBT procedure but photodynamic treatments utilizing photosensitive drugs have had limited success in clinical setting partly because of limitations in light sources and light delivery optics. Bladder is somewhat challenging environment for PDT as it needs to be accessed cystoscopically and lesions might be difficult to target with traditional light delivery optics for example because of their close proximity to bladder entrance. The properties of different tumor types (papillary vs carcinoma in situ (CIS)) also require different illumination methods, so laser parameters and illumination modes need to be designed accordingly.
Modulight has developed its ML7710 laser platform further to optimally support a novel photosensitive drug for treatment of NMIBC in clinical setting. The laser system and its light delivery mechanism enable both focused illumination of localized papillary lesions and overall illumination of the entire bladder to cover possible scattered CIS lesions. Clinicians have been consulted on feasibility of different illumination modes and other practical matters related to e.g., treatment duration. The optimization of Modulight’s system for NMIBC has also included compatibility testing with flexible cystoscopes and investigation of the light delivery system performance in bladder-like environment. Connectivity features of the laser system have been tailored to support documentation requirements in clinical trials by enabling treatment configuration and realized treatment log storage in Modulight Cloud.